{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T23:29:00Z","timestamp":1768260540346,"version":"3.49.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We compared the clinicopathologic features, clinical management, and outcomes of human epidermal growth factor receptor 2 (HER2)\u2013expressing and nonexpressing microinvasive breast carcinomas (MiBC) to explore the significance of HER2 in MiBC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Clinicopathologic and follow-up information of cases with final diagnosis of MiBC with known HER2 status between 2007 and 2019 were analyzed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Nineteen (41.3%) HER2-positive (HER2+) and 27 (58.7%) HER2-negative (HER2\u2212) MiBCs were identified. HER2 positivity was likely to be associated with high nuclear grade, presence of tumor-infiltrating lymphocytes, hormonal receptor negativity, and increased Ki-67 in both microinvasive and associated in situ carcinomas. Nodal metastases were found in 2 ER+\/HER2\u2212 cases (5.3%). One HER2+ case was found to have isolated tumor cells in the axillary node. The majority of patients with HER2+ MiBCs (76.5%) did not receive HER2-targeted therapy. All patients with available follow-up were alive without recurrence or distant metastasis, with a median follow-up of 38 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Similar to the larger size of invasive breast carcinomas, HER2 positivity is associated with high-grade morphologic features in MiBCs. However, HER2 overexpression in MiBCs does not appear to be associated with nodal metastasis or worse outcome in our study cohort. The role of HER2-targeted therapy in this clinical setting merits additional study.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqaa222","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T03:20:23Z","timestamp":1601522423000},"page":"155-165","source":"Crossref","is-referenced-by-count":17,"title":["Significance of HER2 in Microinvasive Breast Carcinoma"],"prefix":"10.1093","volume":"156","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4208-7680","authenticated-orcid":false,"given":"Huina","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana","family":"Moisini","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley M","family":"Turner","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Dhakal","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sierra","family":"Kovar","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda M","family":"Schiffhauer","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G","family":"Hicks","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,1,25]]},"reference":[{"key":"2021061708495545700_CIT0001","volume-title":"TNM Classification of Malignant Tumours","author":"Sobin","year":"1997","edition":"5"},{"key":"2021061708495545700_CIT0002","volume-title":"WHO Classification of Tumours of the Breast","author":"Lakhani","year":"2012","edition":"4"},{"key":"2021061708495545700_CIT0003","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/00000478-200003000-00012","article-title":"Microinvasive carcinoma (T1mic) of the breast: clinicopathologic profile of 21 cases","volume":"24","author":"Prasad","year":"2000","journal-title":"Am J Surg Pathol."},{"key":"2021061708495545700_CIT0004","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1016\/j.humpath.2013.07.010","article-title":"Microinvasive breast carcinoma carries an excellent prognosis regardless of the tumor characteristics","volume":"44","author":"Shatat","year":"2013","journal-title":"Hum Pathol."},{"key":"2021061708495545700_CIT0005","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejso.2018.09.024","article-title":"Microinvasive breast carcinoma: an analysis from ten Senonetwork Italia breast centres","volume":"45","author":"Costarelli","year":"2019","journal-title":"Eur J Surg Oncol."},{"key":"2021061708495545700_CIT0006","first-page":"4332","article-title":"HER-2\/neu amplification predicts poor survival in node-positive breast cancer","volume":"50","author":"Borg","year":"1990","journal-title":"Cancer Res."},{"key":"2021061708495545700_CIT0007","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.1992.10.4.599","article-title":"HER-2\/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma","volume":"10","author":"Allred","year":"1992","journal-title":"J Clin Oncol."},{"key":"2021061708495545700_CIT0008","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/modpathol.3880288","article-title":"Breast cancer in the 21st century: neu opportunities and neu challenges","volume":"14","author":"Schnitt","year":"2001","journal-title":"Mod Pathol."},{"key":"2021061708495545700_CIT0009","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1634\/theoncologist.8-4-307","article-title":"The Her-2\/neu gene and protein in breast cancer 2003: biomarker and target of therapy","volume":"8","author":"Ross","year":"2003","journal-title":"Oncologist."},{"key":"2021061708495545700_CIT0010","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.amjsurg.2016.08.008","article-title":"Incidence, characteristics, and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000 to 2013","volume":"214","author":"Thomas","year":"2017","journal-title":"Am J Surg."},{"key":"2021061708495545700_CIT0011","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1245\/s10434-012-2640-8","article-title":"Microinvasive breast cancer: ER, PR, and HER-2\/neu status and clinical outcomes after breast-conserving therapy or mastectomy","volume":"20","author":"Margalit","year":"2013","journal-title":"Ann Surg Oncol."},{"key":"2021061708495545700_CIT0012","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4048\/jbc.2018.21.2.197","article-title":"Microinvasive carcinoma versus ductal carcinoma in situ: a comparison of clinicopathological features and clinical outcomes","volume":"21","author":"Kim","year":"2018","journal-title":"J Breast Cancer."},{"key":"2021061708495545700_CIT0013","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/1756-0500-7-325","article-title":"Human epidermal growth factor receptor 2-positive microinvasive breast carcinoma with a highly aggressive course: a case report","volume":"7","author":"Kuhar","year":"2014","journal-title":"BMC Res Notes."},{"key":"2021061708495545700_CIT0014","doi-asserted-by":"crossref","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","article-title":"Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists guideline update","volume":"144","author":"Allison","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"2021061708495545700_CIT0015","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med."},{"key":"2021061708495545700_CIT0016","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-40618-3","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017","edition":"8"},{"key":"2021061708495545700_CIT0017","volume-title":"WHO Classification of Tumors of the Breast","author":"WHO Classification of Tumours Editorial Board.","year":"2019","edition":"5"},{"key":"2021061708495545700_CIT0018","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol."},{"key":"2021061708495545700_CIT0019","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12885-018-4013-6","article-title":"Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ","volume":"18","author":"Beguinot","year":"2018","journal-title":"BMC Cancer."},{"key":"2021061708495545700_CIT0020","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/PAI.0b013e3181a1743a","article-title":"Characterization of high-grade ductal carcinoma in situ with and without regressive changes: diagnostic and biologic implications","volume":"17","author":"Chivukula","year":"2009","journal-title":"Appl Immunohistochem Mol Morphol."},{"key":"2021061708495545700_CIT0021","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science."},{"key":"2021061708495545700_CIT0022","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.1200\/JCO.2009.22.0962","article-title":"Clinical relevance of HER2 overexpression\/amplification in patients with small tumor size and node-negative breast cancer","volume":"27","author":"Curigliano","year":"2009","journal-title":"J Clin Oncol."},{"key":"2021061708495545700_CIT0023","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10549-012-2236-9","article-title":"Management of small HER2 overexpressing tumours","volume":"136","author":"Templeton","year":"2012","journal-title":"Breast Cancer Res Treat."},{"key":"2021061708495545700_CIT0024","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/cam4.167","article-title":"HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort","volume":"3","author":"Rouanet","year":"2014","journal-title":"Cancer Med."},{"key":"2021061708495545700_CIT0025","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1245\/s10434-013-2924-7","article-title":"Impact of multifocality and lymph node metastasis on the prognosis and management of microinvasive breast cancer","volume":"20","author":"Kapoor","year":"2013","journal-title":"Ann Surg Oncol."},{"key":"2021061708495545700_CIT0026","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1186\/bcr2128","article-title":"Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer","volume":"10","author":"Tamimi","year":"2008","journal-title":"Breast Cancer Res."},{"key":"2021061708495545700_CIT0027","doi-asserted-by":"crossref","first-page":"42045","DOI":"10.1038\/srep42045","article-title":"The demographic features, clinicopathological characteristics and cancer-specific outcomes for patients with microinvasive breast cancer: a SEER database analysis","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep."},{"key":"2021061708495545700_CIT0028","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1007\/s13277-014-2652-z","article-title":"Clinicopathologic characteristics and molecular subtypes of microinvasive carcinoma of the breast","volume":"36","author":"Wang","year":"2015","journal-title":"Tumour Biol."},{"key":"2021061708495545700_CIT0029","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.breast.2006.03.005","article-title":"A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution","volume":"15","author":"Crowe","year":"2006","journal-title":"Breast."},{"key":"2021061708495545700_CIT0030","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12282-012-0339-0","article-title":"Pathological assessment of microinvasive carcinoma of the breast","volume":"20","author":"Mori","year":"2013","journal-title":"Breast Cancer."},{"key":"2021061708495545700_CIT0031","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1309\/YMJ3A83TB39MRUT9","article-title":"Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas","volume":"123","author":"Lal","year":"2005","journal-title":"Am J Clin Pathol."},{"key":"2021061708495545700_CIT0032","first-page":"109","article-title":"HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer","volume":"4","author":"Zeillinger","year":"1989","journal-title":"Oncogene."},{"key":"2021061708495545700_CIT0033","first-page":"553","article-title":"Comparison of ER, PR and HER-2\/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer","volume":"9","author":"","year":"2008","journal-title":"Asian Pac J Cancer Prev"},{"key":"2021061708495545700_CIT0034","first-page":"8740","article-title":"Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features","volume":"7","author":"Ning","year":"2014","journal-title":"Int J Clin Exp Pathol."},{"key":"2021061708495545700_CIT0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jsbmb.2006.09.008","article-title":"Co-expression of steroid receptors (estrogen receptor alpha and\/or progesterone receptors) and Her-2\/neu: clinical implications","volume":"102","author":"Ciocca","year":"2006","journal-title":"J Steroid Biochem Mol Biol."},{"key":"2021061708495545700_CIT0036","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/jclinpath-2015-203506","article-title":"Two progressive pathways of microinvasive carcinoma: low-grade luminal pathway and high-grade HER2 pathway based on high tumour-infiltrating lymphocytes","volume":"69","author":"Morita","year":"2016","journal-title":"J Clin Pathol."},{"key":"2021061708495545700_CIT0037","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","article-title":"Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer","volume":"29","author":"Mahmoud","year":"2011","journal-title":"J Clin Oncol."},{"key":"2021061708495545700_CIT0038","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1158\/1078-0432.CCR-15-2338","article-title":"Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant-treated HER2-positive breast cancer","volume":"22","author":"Ingold Heppner","year":"2016","journal-title":"Clin Cancer Res."},{"key":"2021061708495545700_CIT0039","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/jamaoncol.2015.0830","article-title":"Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial","volume":"1","author":"Salgado","year":"2015","journal-title":"JAMA Oncol."},{"key":"2021061708495545700_CIT0040","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","article-title":"Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers","volume":"33","author":"Denkert","year":"2015","journal-title":"J Clin Oncol."},{"key":"2021061708495545700_CIT0041","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1200\/JCO.19.00066","article-title":"Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer","volume":"37","author":"Tolaney","year":"2019","journal-title":"J Clin Oncol."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajcp\/article-pdf\/156\/1\/155\/38667503\/aqaa222.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajcp\/article-pdf\/156\/1\/155\/38667503\/aqaa222.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T08:50:56Z","timestamp":1623919856000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/156\/1\/155\/6118474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,25]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,25]]},"published-print":{"date-parts":[[2021,6,17]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqaa222","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2021,1,25]]}}}